解码巴贝里根的治疗网络:对IBS-D的协同解决方案
Qi Yan1, Xufei Wang1, Huijiao Jiang1
1Department of Immunology, School of Medicine, Shihezi University, Shihezi, Xinjiang, China.
Combinatorial chemistry & high throughput screening
|September 18, 2025
概括
胡桃根 (Sankezhen) 通过减少炎症和调节肠道运动来缓解腹占主导地位的刺激性肠综合征 (IBS-D). 这项研究确定了关键化合物和分子标,揭示了其多途径治疗潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
- 胃肠病学 胃肠病学
背景情况:
- 腹占主导地位的刺激性肠综合征 (IBS-D) 是一种普遍存在的胃肠道疾病.
- 传统的维吾尔医学使用根 (Sankezhen, SKZ) 治疗IBS-D.
- 基于SKZ在IBS-D治疗中的疗效的分子机制尚不清楚.
研究的目的:
- 通过计算预测和实验验证IBS-D.SKZ的治疗标和分子途径.
- 阐明SKZ在缓解IBS-D症状中的协同机制.
主要方法:
- 使用多个数据库 (TCM-Suite,BATMAN-TCM) 识别了SKZ的生物活性化合物和标.
- 从DisGeNET和GeneCards收集了IBS-D的目标.
- 使用了网络药理学 (PPI,GO,KEGG) 和分子对接/动力学模拟.
- 为了验证,进行了体外 (巨细胞) 和体内 (IBS-D大鼠模型) 实验.
主要成果:
- 确定了15个活性化合物和85个重叠目标,优先考虑四个关键化合物和15个枢纽目标.
- 丰富分析表明,SKZ标参与炎症和肠道运动途径.
- SKZ 显示出抗炎作用,降低了关键基因 (CHAT,C-FOS,5-HT3R,5-HT4R) 的调节,并抑制了肠道收缩.
结论:
- 通过多路调节,SKZ在改善IBS-D方面表现出协同效应.
- 这种草药可能通过涉及炎症 (NF-κB/MAPK),神经传递 (胆固醇/5-HT) 和离子通道的途径起作用.
- 这些发现支持了SKZ在IBS-D中的治疗作用,因此需要对单个化合物的进一步研究.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
635
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
635
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Drugs for Treatment of Constipation-Predominant IBS
726
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
726
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
732
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
732
Irritable Bowel Syndrome III: Medical and Nursing Management
643
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
643
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528


